FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2055753691> ?p ?o ?g. }

• W2055753691 endingPage "49" @default.
• W2055753691 startingPage "49" @default.
• W2055753691 abstract "Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies Anja Schweizer1, Sylvie Dejager2, James E Foley3, Wolfgang Kothny31Novartis Pharma AG, Basel, Switzerland; 2Novartis Pharma SAS, Rueil-Malmaison, France; 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAAim: Analyzing safety aspects of a drug from individual studies can lead to difficult-to-interpret results. The aim of this paper is therefore to assess the general safety and tolerability, including incidences of the most common adverse events (AEs), of vildagliptin based on a large pooled database of Phase II and III clinical trials.Methods: Safety data were pooled from 38 studies of ≥12 to ≥104 weeks&#39; duration. AE profiles of vildagliptin (50 mg bid; N = 6116) were evaluated relative to a pool of comparators (placebo and active comparators; N = 6210). Absolute incidence rates were calculated for all AEs, serious AEs (SAEs), discontinuations due to AEs, and deaths.Results: Overall AEs, SAEs, discontinuations due to AEs, and deaths were all reported with a similar frequency in patients receiving vildagliptin (69.1%, 8.9%, 5.7%, and 0.4%, respectively) and patients receiving comparators (69.0%, 9.0%, 6.4%, and 0.4%, respectively), whereas drug-related AEs were seen with a lower frequency in vildagliptin-treated patients (15.7% vs 21.7% with comparators). The incidences of the most commonly reported specific AEs were also similar between vildagliptin and comparators, except for increased incidences of hypoglycemia, tremor, and hyperhidrosis in the comparator group related to the use of sulfonylureas.Conclusions: The present pooled analysis shows that vildagliptin was overall well tolerated in clinical trials of up to >2 years in duration. The data further emphasize the value of a pooled analysis from a large safety database versus assessing safety and tolerability from individual studies.Keywords: type 2 diabetes, dipeptidyl peptidase-4, edema, safety, vildagliptin" @default.
• W2055753691 created "2016-06-24" @default.
• W2055753691 creator A5007864342 @default.
• W2055753691 creator A5025969627 @default.
• W2055753691 creator A5066047147 @default.
• W2055753691 creator A5068333266 @default.
• W2055753691 date "2011-02-01" @default.
• W2055753691 modified "2023-10-18" @default.
• W2055753691 title "Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies" @default.
• W2055753691 cites W1969389642 @default.
• W2055753691 cites W1970406523 @default.
• W2055753691 cites W1973383046 @default.
• W2055753691 cites W1977619586 @default.
• W2055753691 cites W1979982110 @default.
• W2055753691 cites W1982067008 @default.
• W2055753691 cites W1984588810 @default.
• W2055753691 cites W1989976483 @default.
• W2055753691 cites W1991565451 @default.
• W2055753691 cites W1991951001 @default.
• W2055753691 cites W2020638064 @default.
• W2055753691 cites W2024567427 @default.
• W2055753691 cites W2027249582 @default.
• W2055753691 cites W2047353065 @default.
• W2055753691 cites W2049323977 @default.
• W2055753691 cites W2059241568 @default.
• W2055753691 cites W2063976195 @default.
• W2055753691 cites W2074925580 @default.
• W2055753691 cites W2079787842 @default.
• W2055753691 cites W2089443047 @default.
• W2055753691 cites W2099677425 @default.
• W2055753691 cites W2101293928 @default.
• W2055753691 cites W2103828712 @default.
• W2055753691 cites W2107562831 @default.
• W2055753691 cites W2117762041 @default.
• W2055753691 cites W2119114384 @default.
• W2055753691 cites W2124465362 @default.
• W2055753691 cites W2137471483 @default.
• W2055753691 cites W2140369318 @default.
• W2055753691 cites W2167621077 @default.
• W2055753691 doi "https://doi.org/10.2147/vhrm.s16925" @default.
• W2055753691 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3049539" @default.
• W2055753691 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21415917" @default.
• W2055753691 hasPublicationYear "2011" @default.
• W2055753691 type Work @default.
• W2055753691 sameAs 2055753691 @default.
• W2055753691 citedByCount "51" @default.
• W2055753691 countsByYear W20557536912012 @default.
• W2055753691 countsByYear W20557536912013 @default.
• W2055753691 countsByYear W20557536912014 @default.
• W2055753691 countsByYear W20557536912015 @default.
• W2055753691 countsByYear W20557536912016 @default.
• W2055753691 countsByYear W20557536912017 @default.
• W2055753691 countsByYear W20557536912019 @default.
• W2055753691 countsByYear W20557536912020 @default.
• W2055753691 countsByYear W20557536912021 @default.
• W2055753691 crossrefType "journal-article" @default.
• W2055753691 hasAuthorship W2055753691A5007864342 @default.
• W2055753691 hasAuthorship W2055753691A5025969627 @default.
• W2055753691 hasAuthorship W2055753691A5066047147 @default.
• W2055753691 hasAuthorship W2055753691A5068333266 @default.
• W2055753691 hasBestOaLocation W20557536911 @default.
• W2055753691 hasConcept C120665830 @default.
• W2055753691 hasConcept C121332964 @default.
• W2055753691 hasConcept C126322002 @default.
• W2055753691 hasConcept C142724271 @default.
• W2055753691 hasConcept C197934379 @default.
• W2055753691 hasConcept C204787440 @default.
• W2055753691 hasConcept C27081682 @default.
• W2055753691 hasConcept C2776453732 @default.
• W2055753691 hasConcept C2778375690 @default.
• W2055753691 hasConcept C2779306644 @default.
• W2055753691 hasConcept C2780323712 @default.
• W2055753691 hasConcept C61511704 @default.
• W2055753691 hasConcept C71924100 @default.
• W2055753691 hasConcept C98274493 @default.
• W2055753691 hasConceptScore W2055753691C120665830 @default.
• W2055753691 hasConceptScore W2055753691C121332964 @default.
• W2055753691 hasConceptScore W2055753691C126322002 @default.
• W2055753691 hasConceptScore W2055753691C142724271 @default.
• W2055753691 hasConceptScore W2055753691C197934379 @default.
• W2055753691 hasConceptScore W2055753691C204787440 @default.
• W2055753691 hasConceptScore W2055753691C27081682 @default.
• W2055753691 hasConceptScore W2055753691C2776453732 @default.
• W2055753691 hasConceptScore W2055753691C2778375690 @default.
• W2055753691 hasConceptScore W2055753691C2779306644 @default.
• W2055753691 hasConceptScore W2055753691C2780323712 @default.
• W2055753691 hasConceptScore W2055753691C61511704 @default.
• W2055753691 hasConceptScore W2055753691C71924100 @default.
• W2055753691 hasConceptScore W2055753691C98274493 @default.
• W2055753691 hasLocation W20557536911 @default.
• W2055753691 hasLocation W20557536912 @default.
• W2055753691 hasLocation W20557536913 @default.
• W2055753691 hasLocation W20557536914 @default.
• W2055753691 hasLocation W20557536915 @default.
• W2055753691 hasOpenAccess W2055753691 @default.
• W2055753691 hasPrimaryLocation W20557536911 @default.
• W2055753691 hasRelatedWork W1966047811 @default.
• W2055753691 hasRelatedWork W2003042623 @default.

• next